FDA approves Orca Bio's Tregzi after Precision-T cut chronic GVHD-free survival gap
The Phase 3 Precision-T trial showed 78% of Tregzi recipients free of chronic GVHD or death at 12 months versus 38% on standard transplant, and the FDA approved the cell therapy days ahead of its July 6 target date.
Executive Summary
- The FDA approved Orca Bio's cell therapy for adults receiving a matched-donor stem cell transplant for blood cancers, resolving a Biologics License Application review days ahead of its target date.
- The approval rests on a randomized Phase 3 trial that showed the therapy roughly doubled the rate of patients living free of chronic graft-versus-host disease or death a year after transplant, compared with a conventional transplant regimen.
- This is the first approval of a purified regulatory T-cell therapy in transplant medicine, giving physicians a manufactured cellular alternative to the decades-old drug regimen used to prevent graft-versus-host disease.
- Orca Bio had already built out bicoastal manufacturing capacity ahead of the decision, positioning the company to begin supplying the therapy without a post-approval scale-up delay.
The decision
The FDA approved Tregzi, known clinically as Orca-T, for use in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, to support immune reconstitution and improve chronic graft-versus-host-disease-free survival in adults with hematologic malignancies. Orca Bio announced the decision on June 30, 2026, ahead of the Biologics License Application's July 6, 2026 target action date. The therapy had carried Regenerative Medicine Advanced Therapy and Orphan Drug designations from the FDA heading into the review. Orca+1Orca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with Hematological MalignanciesJun 30, 2026Orca Bio Adds East Coast Manufacturing Capacity and Triples West Coast Manufacturing Workforce Ahead of Potential Orca-T® LaunchJun 15, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The trial and its result
The approval is based on Precision-T (NCT05316701), a randomized, open-label Phase 3 study that enrolled 187 patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome or mixed-phenotype acute leukemia, all matched 8/8 to a donor and undergoing myeloablative conditioning. The trial randomized patients to Tregzi plus single-agent tacrolimus or to a conventional allogeneic transplant plus tacrolimus and methotrexate, with chronic graft-versus-host-disease-free survival at 12 months adjudicated by an independent committee as the primary endpoint. At 12 months, 78% of Tregzi recipients were free of chronic graft-versus-host disease or death, versus 38% on the conventional regimen, a hazard ratio of 0.26 (p<0.00001). Chronic graft-versus-host disease itself occurred in 13% of Tregzi recipients versus 44% on standard care, a hazard ratio of 0.19 (p<0.00002). Serious adverse events were reported in 34 of 88 at-risk Tregzi patients versus 53 of 94 on standard care, with 3 deaths on the Tregzi arm versus 9 on standard care. NCT05316701+1Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesNCT05316701Orca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with Hematological MalignanciesJun 30, 2026
Where it sits in the field
Cell therapy has been used sparingly in hematologic malignancies relative to small-molecule and antibody approaches: 17 trials have used non-CAR cell therapy modalities across the indication, a narrow share of the broader field. Other Phase 3 programs in acute myeloid leukemia target distinct mechanisms, including Syndax Pharmaceuticals' menin inhibitor revumenib, Daiichi Sankyo's FLT3 inhibitor quizartinib, and AbbVie's CD123-directed antibody-drug conjugate pivekimab sunirine, none of which addresses graft-versus-host disease directly. Miguel-Angel Perales, chief of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, said the approval "signals a new era in transplant medicine" and could let providers "reduce serious toxicities and improve treatment outcomes" relative to conventional transplant. No other program in the reviewed field applies purified regulatory T-cell selection to this transplant setting, leaving the randomized Phase 3 separation from standard tacrolimus/methotrexate as the direct evidentiary bar this approval had to clear. OrcaOrca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with Hematological MalignanciesJun 30, 2026
Operational context
The trial's registered primary completion date moved from an original April 2024 target out to April 2025 in 2024, then was pulled back in to July 15, 2024 in April 2025, alongside two rounds of eligibility-criteria amendments. Enrollment held flat at its final count of 187 patients, within the routine range for a completed registrational trial. Orca Bio had tripled its Sacramento manufacturing workforce and added a Princeton, New Jersey facility in the weeks before the decision, to support commercial-scale delivery of a therapy manufactured individually from donor cells. NCT05316701+1Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesNCT05316701Orca Bio Adds East Coast Manufacturing Capacity and Triples West Coast Manufacturing Workforce Ahead of Potential Orca-T® LaunchJun 15, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.